US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Definium Therapeutics

36.90

+2.727.96%

Post-market: 36.920.0170+0.05%18:14 EDT

Volume:2.77M

Turnover:102.48M

Market Cap:4.96B

PE:-10.60

High:38.04

Open:34.85

Low:34.57

Close:34.18

52wk High:49.70

52wk Low:10.46

Shares:134.37M

Float Shares:129.97M

Volume Ratio:1.29

T/O Rate:2.13%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.4823

EPS(LYR):-2.0600

ROE:-64.09%

ROA:-20.64%

PB:5.40

PE(LYR):-17.91

Loading ...

Overview Company News Filings

BRIEF-Definium Therapeutics Says Study Of DT120 ODT Met Primary All Key Secondary Efficacy Endpoints

Definium Therapeutics: Positive Topline Results From Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (Odt) in Major Depressive Disorder

THOMSON REUTERS

Definium Therapeutics: Study of DT120 Orally Disintegrating Tablet Met Primary & All Key Secondary Efficacy Endpoints

THOMSON REUTERS

Definium Therapeutics: DT120 Odt Was Generally Well Tolerated With No Serious Adverse Events or Suicidality Signal

THOMSON REUTERS

U.S. RESEARCH ROUNDUP-Baldwin Insurance Group, Diamondback Energy, Visteon

Definium Therapeutics to present Phase 3 Emerge topline data for DT120 ODT in major depressive disorder June 22

Definium Therapeutics to Discuss Topline Results From Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026

THOMSON REUTERS

Definium Therapeutics Is Maintained at Buy by Canaccord Genuity

Definium Therapeutics issues inducement stock options for 155,480 shares to new hires

Definium Therapeutics Shareholders Approve All Annual Meeting Proposals

Definium Therapeutics shareholders approve 5 million-share increase to equity incentive plan

Definium Therapeutics issues inducement stock options for 462,190 shares to new hires

Definium Therapeutics to join Jefferies Global Healthcare Conference fireside chat

Definium Therapeutics Nears Pivotal Earnings Call Tests

LifeSci Capital Remains a Buy on Definium Therapeutics (DFTX)

Stock Track | Definium Therapeutics Soars 5.15% Intraday After Analyst Reiterates Buy Rating with $70 Price Target on Pipeline Confidence

Definium Therapeutics: Buy Rating Reiterated with Unchanged $70 Price Target on Robust Late-Stage DT120 Pipeline and De-Risked Phase 3 Programs

Definium Therapeutics says first patient dosed in Ascend study

BRIEF-Definium Therapeutics Announces First Patient Dosed In Ascend

Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 Odt in Major Depressive Disorder

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/DFTX/news?page=10"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DFTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DFTX\",,,,,undefined,":{"symbol":"DFTX","market":"US","secType":"STK","nameCN":"Definium Therapeutics","latestPrice":36.9,"timestamp":1791576000000,"preClose":34.18,"halted":0,"volume":2773276,"hourTrading":{"tag":"盘后","latestPrice":36.917,"preClose":36.9,"latestTime":"18:14 EDT","volume":37004,"amount":1365505.955308,"timestamp":1791584095723,"change":0.017,"changeRate":0.000461,"amplitude":0.024119},"delay":0,"changeRate":0.07957870099473373,"floatShares":129971489,"shares":134366950,"eps":-3.482311,"marketStatus":"Post-Mkt","change":2.72,"latestTime":"10-09 18:19:02 EDT","open":34.85,"high":38.04,"low":34.5701,"amount":102477395.88644801,"amplitude":0.101518,"askPrice":37.62,"askSize":53,"bidPrice":36.55,"bidSize":50,"shortable":3,"etf":0,"ttmEps":-3.482311,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1791590400000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":34.18,"preHourTrading":{"tag":"盘前","latestPrice":34.86,"preClose":34.18,"latestTime":"09:29 EDT","volume":8156,"amount":289205.96924,"timestamp":1791552599999,"change":0.68,"changeRate":0.019895,"amplitude":0.061147},"postHourTrading":{"tag":"盘后","latestPrice":36.917,"preClose":36.9,"latestTime":"18:14 EDT","volume":37004,"amount":1365505.955308,"timestamp":1791584095723,"change":0.017,"changeRate":0.000461,"amplitude":0.024119},"volumeRatio":1.28943,"impliedVol":0.5805,"impliedVolPercentile":0.0054},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DFTX\",,,,,undefined,":{"symbol":"DFTX","floatShares":129971489,"roa":"-20.64%","roe":"-64.09%","lyrEps":-2.059999,"volumeRatio":1.28943,"shares":134366950,"dividePrice":0,"high":38.04,"amplitude":0.101518,"preClose":34.18,"low":34.5701,"week52Low":10.4646,"pbRate":"5.40","week52High":49.7,"institutionHeld":0,"latestPrice":36.9,"committee":-0.029126,"eps":-3.482311,"divideRate":0,"volume":2773276,"delay":0,"ttmEps":-3.482311,"open":34.85,"prevYearClose":13.39,"prevWeekClose":37.4,"prevMonthClose":38.06,"prevQuarterClose":38.06,"fiveDayClose":37.4,"twentyDayClose":38.89,"sixtyDayClose":44.1},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DFTX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-06","symbol":"DFTX","fiscalQuarterEnding":"2026/06","expectedEps":-0.55,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1785988800000,"reportTimeType":"post","actualEps":-1.44},{"market":"US","date":"2026-05-07","symbol":"DFTX","fiscalQuarterEnding":"2026/03","expectedEps":-0.47,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"post","actualEps":-0.71},{"market":"US","date":"2026-02-26","symbol":"DFTX","fiscalQuarterEnding":"2025/12","expectedEps":-0.45,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1772082000000,"reportTimeType":"post","actualEps":-0.45}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DFTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"DFTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3889,"buy":0.6111,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6111,"analysts":18,"updateTime":1787025600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/DFTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"DFTX","date":"2026-10-08","current":-10.596411,"percent":0.417582,"low":-27.074722,"twenty":-17.041551,"median":-11.678904,"eighty":-9.948453,"high":-8.802064,"avg":-13.976636,"sd":5.118646,"marketCap":4714936275},"quantilePoints":[{"date":"2026-01-16","current":-9.013032,"twenty":-8.970838,"median":-8.907548,"eighty":-8.844258,"marketCap":1515072711},{"date":"2026-01-23","current":-9.944809,"twenty":-9.944809,"median":-9.423248,"eighty":-8.819645,"marketCap":1671702464},{"date":"2026-01-30","current":-10.103035,"twenty":-10.103035,"median":-9.868626,"eighty":-9.013032,"marketCap":1698299969},{"date":"2026-02-06","current":-9.522872,"twenty":-10.196799,"median":-9.918438,"eighty":-9.522872,"marketCap":1600775783},{"date":"2026-02-13","current":-9.511152,"twenty":-10.179218,"median":-9.944809,"eighty":-9.522872,"marketCap":1598805598},{"date":"2026-02-20","current":-10.120616,"twenty":-10.18039,"median":-9.944809,"eighty":-9.520528,"marketCap":1701255248},{"date":"2026-02-27","current":-9.267085,"twenty":-10.187422,"median":-9.96239,"eighty":-9.520528,"marketCap":1703225433},{"date":"2026-03-06","current":-9.519961,"twenty":-10.18039,"median":-9.903787,"eighty":-9.502065,"marketCap":1749702163},{"date":"2026-03-13","current":-9.753213,"twenty":-10.18039,"median":-9.918437,"eighty":-9.518199,"marketCap":1792572359},{"date":"2026-03-20","current":-10.122078,"twenty":-10.169841,"median":-9.903787,"eighty":-9.52229,"marketCap":1860367087},{"date":"2026-03-27","current":-10.273963,"twenty":-10.169841,"median":-9.918437,"eighty":-9.559599,"marketCap":1888282563},{"date":"2026-04-02","current":-11.174427,"twenty":-10.181562,"median":-9.918437,"eighty":-9.550417,"marketCap":2053781457},{"date":"2026-04-10","current":-11.619234,"twenty":-10.247114,"median":-9.944809,"eighty":-9.57529,"marketCap":2135533923},{"date":"2026-04-17","current":-12.18338,"twenty":-10.396104,"median":-9.980506,"eighty":-9.589394,"marketCap":2239219977},{"date":"2026-04-24","current":-12.617338,"twenty":-11.167918,"median":-10.038572,"eighty":-9.618687,"marketCap":2318978480},{"date":"2026-05-01","current":-11.86876,"twenty":-11.389236,"median":-10.10442,"eighty":-9.643639,"marketCap":2181395062},{"date":"2026-05-08","current":-13.767387,"twenty":-11.71579,"median":-10.122078,"eighty":-9.665202,"marketCap":2530349365},{"date":"2026-05-15","current":-9.802755,"twenty":-11.643102,"median":-10.113211,"eighty":-9.689477,"marketCap":2328575817},{"date":"2026-05-22","current":-10.399644,"twenty":-11.570414,"median":-10.105791,"eighty":-9.636028,"marketCap":2470362634},{"date":"2026-05-29","current":-10.780735,"twenty":-11.483622,"median":-10.120616,"eighty":-9.642537,"marketCap":2560888064},{"date":"2026-06-05","current":-11.290386,"twenty":-11.393576,"median":-10.145827,"eighty":-9.660184,"marketCap":2681952193},{"date":"2026-06-12","current":-11.069996,"twenty":-11.344489,"median":-10.179218,"eighty":-9.68473,"marketCap":2629600138},{"date":"2026-06-18","current":-11.216923,"twenty":-11.349156,"median":-10.196799,"eighty":-9.702279,"marketCap":2664501508},{"date":"2026-06-26","current":-20.565124,"twenty":-11.510745,"median":-10.247973,"eighty":-9.723056,"marketCap":4885101210},{"date":"2026-07-02","current":-24.252692,"twenty":-11.77112,"median":-10.299843,"eighty":-9.753213,"marketCap":5761057223},{"date":"2026-07-10","current":-27.074722,"twenty":-12.069466,"median":-10.333633,"eighty":-9.796609,"marketCap":6431410656},{"date":"2026-07-17","current":-24.643864,"twenty":-12.519698,"median":-10.492938,"eighty":-9.802755,"marketCap":5853977501},{"date":"2026-07-24","current":-23.990048,"twenty":-12.931958,"median":-10.537388,"eighty":-9.812883,"marketCap":5698667894},{"date":"2026-07-31","current":-24.861803,"twenty":-14.440728,"median":-10.67054,"eighty":-9.817222,"marketCap":5905747370},{"date":"2026-08-07","current":-17.312135,"twenty":-19.588062,"median":-10.789918,"eighty":-9.824231,"marketCap":6124773739},{"date":"2026-08-14","current":-16.673146,"twenty":-17.887875,"median":-10.831241,"eighty":-9.831914,"marketCap":5898709105},{"date":"2026-08-21","current":-17.242844,"twenty":-17.526933,"median":-11.058518,"eighty":-9.861594,"marketCap":6100259530},{"date":"2026-08-28","current":-16.642763,"twenty":-17.426666,"median":-11.092954,"eighty":-9.887379,"marketCap":5887959749},{"date":"2026-09-04","current":-14.432336,"twenty":-17.33018,"median":-11.139168,"eighty":-9.901443,"marketCap":5105944100},{"date":"2026-09-11","current":-14.329791,"twenty":-17.27056,"median":-11.195675,"eighty":-9.903787,"marketCap":5069665023},{"date":"2026-09-18","current":-14.690599,"twenty":-17.210941,"median":-11.23988,"eighty":-9.921368,"marketCap":5197313626},{"date":"2026-09-25","current":-13.949992,"twenty":-17.164605,"median":-11.372203,"eighty":-9.935823,"marketCap":4935298073},{"date":"2026-10-02","current":-14.280417,"twenty":-17.093203,"median":-11.537867,"eighty":-9.941944,"marketCap":5052197320},{"date":"2026-10-08","current":-13.327123,"twenty":-17.041551,"median":-11.678904,"eighty":-9.948453,"marketCap":4714936275}],"updateTime":1791584342223},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DFTX\",pageSize:20,pageCount:10,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2645024357","title":"BRIEF-Definium Therapeutics Says Study Of DT120 ODT Met Primary All Key Secondary Efficacy Endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2645024357","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645024357?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:00","pubTimestamp":1782126001,"startTime":"0","endTime":"0","summary":"BRIEF-Definium Therapeutics Says Study Of DT120 ODT Met Primary All Key Secondary Efficacy EndpointsJune 22  - Definium Therapeutics Inc DFTX.O:DEFINIUM THERAPEUTICS: POSITIVE TOPLINE RESULTS FROM PHASE 3 EMERGE STUDY OF DT120 ORALLY DISINTEGRATING TABLET  IN MAJOR DEPRESSIVE DISORDERDEFINIUM THERAPEUTICS: STUDY OF DT120 ORALLY DISINTEGRATING TABLET MET PRIMARY  ALL KEY SECONDARY EFFICACY ENDPOINTSDEFINIUM THERAPEUTICS: DT120 ODT WAS GENERALLY WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTS OR SUICIDALITY SIGNAL ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nP8N42502Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645293100","title":"Definium Therapeutics: Positive Topline Results From Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (Odt) in Major Depressive Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2645293100","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645293100?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:00","pubTimestamp":1782126000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nP8N42502Y:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645029348","title":"Definium Therapeutics: Study of DT120 Orally Disintegrating Tablet Met Primary & All Key Secondary Efficacy Endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2645029348","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645029348?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:00","pubTimestamp":1782126000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nP8N42502Y:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645029317","title":"Definium Therapeutics: DT120 Odt Was Generally Well Tolerated With No Serious Adverse Events or Suicidality Signal","url":"https://stock-news.laohu8.com/highlight/detail?id=2645029317","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645029317?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:00","pubTimestamp":1782126000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nP8N42502Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645042865","title":"U.S. RESEARCH ROUNDUP-Baldwin Insurance Group, Diamondback Energy, Visteon","url":"https://stock-news.laohu8.com/highlight/detail?id=2645042865","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645042865?lang=en_us&edition=fundamental","pubTime":"2026-06-22 15:47","pubTimestamp":1782114448,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Baldwin Insurance Group, Diamondback Energy, VisteonJune 22 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nL4N42U0H9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DAR","CHRD","FANG","VC","ENPH","LRCU","ARMK","BWXT","MULL","NBIX","BWIN","AMAT","INTC","AAL","ABVX","LINT","FPS","KR","AMRZ","HCA","AALG","LGN","DFTX","DAL","CNXU","ALGM","MTDR","MRK","KLAG","INCY","MRNY","INTW","LRCX","ALT","BYD","DCH","MRNA","FTH","BILL","KLAC","GLW","FMC","MRNX","AGMB","MU","APGE","MUU","KMX","LQDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645164840","title":"Definium Therapeutics to present Phase 3 Emerge topline data for DT120 ODT in major depressive disorder June 22","url":"https://stock-news.laohu8.com/highlight/detail?id=2645164840","media":"Reuters","labels":["dataReport","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645164840?lang=en_us&edition=fundamental","pubTime":"2026-06-22 05:00","pubTimestamp":1782075628,"startTime":"0","endTime":"0","summary":"Definium Therapeutics scheduled a June 22, 2026 webcast to present topline Phase 3 Emerge results for DT120 ODT in major depressive disorder.The trial tested a single-dose treatment against placebo, with efficacy assessed over several weeks.Management plans to discuss whether DT120 produced meaningful symptom improvement versus placebo, alongside the overall safety profile, without releasing detailed metrics in advance.Emerge is the first of two pivotal Phase 3 studies; a second trial, Ascend, is running with an additional lower-dose arm to support the program.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Definium Therapeutics Inc. published the original content used to generate this news brief via Business Wire  on June 21, 2026, an","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260621:nNDL6nkKwk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645016483","title":"Definium Therapeutics to Discuss Topline Results From Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2645016483","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645016483?lang=en_us&edition=fundamental","pubTime":"2026-06-22 05:00","pubTimestamp":1782075601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260621:nTUA1K8DQB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644766231","title":"Definium Therapeutics Is Maintained at Buy by Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2644766231","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644766231?lang=en_us&edition=fundamental","pubTime":"2026-06-16 23:59","pubTimestamp":1781625540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/DFTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 16, 2026 11:59 ET (15:59 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643785383","title":"Definium Therapeutics issues inducement stock options for 155,480 shares to new hires","url":"https://stock-news.laohu8.com/highlight/detail?id=2643785383","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643785383?lang=en_us&edition=fundamental","pubTime":"2026-06-16 04:01","pubTimestamp":1781553672,"startTime":"0","endTime":"0","summary":"Definium Therapeutics issued inducement stock options covering 155,480 common shares to six newly hired non-executive employees.Options carry an exercise price set at the closing share price on June 15, 2026.Vesting spans four years: 25% after one year, remaining 75% in substantially equal monthly installments over the next three years.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nNDL9m0ZGF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643740215","title":"Definium Therapeutics Shareholders Approve All Annual Meeting Proposals","url":"https://stock-news.laohu8.com/highlight/detail?id=2643740215","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643740215?lang=en_us&edition=fundamental","pubTime":"2026-06-13 07:05","pubTimestamp":1781305522,"startTime":"0","endTime":"0","summary":"Definium Therapeutics ( ($DFTX) ) has issued an announcement. On June 11, 2026, Definium Therapeutics, Inc. held its Annual Meeting, where a quorum...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/definium-therapeutics-shareholders-approve-all-annual-meeting-proposals?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/definium-therapeutics-shareholders-approve-all-annual-meeting-proposals?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643940218","title":"Definium Therapeutics shareholders approve 5 million-share increase to equity incentive plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2643940218","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643940218?lang=en_us&edition=fundamental","pubTime":"2026-06-13 04:31","pubTimestamp":1781296272,"startTime":"0","endTime":"0","summary":"Definium Therapeutics held its annual general and special meeting of shareholders on June 11, 2026.Shareholders passed an amendment to the 2025 Equity Incentive Plan, lifting the share reserve by 5 million common shares; the amendment took effect on approval.KPMG LLP was reappointed as independent registered public accounting firm through the 2027 annual meeting.Shareholders also voted in favor of the company’s slate of seven board nominees to serve until the 2027 annual meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Definium Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Comm","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nNDL7ZF4y7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640884964","title":"Definium Therapeutics issues inducement stock options for 462,190 shares to new hires","url":"https://stock-news.laohu8.com/highlight/detail?id=2640884964","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640884964?lang=en_us&edition=fundamental","pubTime":"2026-06-02 04:01","pubTimestamp":1780344086,"startTime":"0","endTime":"0","summary":"Definium Therapeutics issued inducement stock options covering 462,190 common shares to 13 newly hired non-executive employees.Grants carry effective dates of May 18, 2026, and June 1, 2026; exercise price set at the closing share price on each grant date.Award schedule calls for 25% vesting on the first anniversary, with the remaining 75% vesting in roughly equal monthly installments over three years.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDLbQnqPV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637738033","title":"Definium Therapeutics to join Jefferies Global Healthcare Conference fireside chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2637738033","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637738033?lang=en_us&edition=fundamental","pubTime":"2026-05-21 19:01","pubTimestamp":1779361278,"startTime":"0","endTime":"0","summary":"Definium Therapeutics management to join a fireside chat at the Jefferies Global Healthcare Conference in New York on June 3, 2026 at 3:10 p.m. EDT.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Definium Therapeutics Inc. published the original content used to generate this news brief via Business Wire  on May 21, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDL4d9jmd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636813319","title":"Definium Therapeutics Nears Pivotal Earnings Call Tests","url":"https://stock-news.laohu8.com/highlight/detail?id=2636813319","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636813319?lang=en_us&edition=fundamental","pubTime":"2026-05-20 13:49","pubTimestamp":1779256195,"startTime":"0","endTime":"0","summary":"Definium Therapeutics, Inc. (($DFTX)) has held its Q1 earnings call. Read on for the main highlights of the call. Definium Therapeutics’ latest ear...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/definium-therapeutics-nears-pivotal-earnings-call-tests?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/definium-therapeutics-nears-pivotal-earnings-call-tests?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635665210","title":"LifeSci Capital Remains a Buy on Definium Therapeutics (DFTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635665210","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635665210?lang=en_us&edition=fundamental","pubTime":"2026-05-16 22:35","pubTimestamp":1778942151,"startTime":"0","endTime":"0","summary":"In a report released today, Francois Brisebois from LifeSci Capital maintained a Buy rating on Definium Therapeutics, with a price target of $38.00...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lifesci-capital-remains-a-buy-on-definium-therapeutics-dftx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lifesci-capital-remains-a-buy-on-definium-therapeutics-dftx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138713954","title":"Stock Track | Definium Therapeutics Soars 5.15% Intraday After Analyst Reiterates Buy Rating with $70 Price Target on Pipeline Confidence","url":"https://stock-news.laohu8.com/highlight/detail?id=1138713954","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138713954?lang=en_us&edition=fundamental","pubTime":"2026-05-14 01:45","pubTimestamp":1778694302,"startTime":"0","endTime":"0","summary":"Definium Therapeutics (DFTX) stock soared 5.15% during intraday trading on Wednesday, marking a significant upward movement.The surge follows a positive analyst note from H.C. Wainwright, where...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635090783","title":"Definium Therapeutics: Buy Rating Reiterated with Unchanged $70 Price Target on Robust Late-Stage DT120 Pipeline and De-Risked Phase 3 Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2635090783","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635090783?lang=en_us&edition=fundamental","pubTime":"2026-05-13 18:35","pubTimestamp":1778668536,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Patrick Trucchio has reiterated their bullish stance on DFTX stock, giving a Buy rating today. Patrick Trucchio has given h...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/definium-therapeutics-buy-rating-reiterated-with-unchanged-70-price-target-on-robust-late-stage-dt120-pipeline-and-de-risked-phase-3-programs-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/definium-therapeutics-buy-rating-reiterated-with-unchanged-70-price-target-on-robust-late-stage-dt120-pipeline-and-de-risked-phase-3-programs-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DFTX","SSI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634111902","title":"Definium Therapeutics says first patient dosed in Ascend study","url":"https://stock-news.laohu8.com/highlight/detail?id=2634111902","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634111902?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:39","pubTimestamp":1778589593,"startTime":"0","endTime":"0","summary":"Definium Therapeutics (DFTX) announced that the first patient has been dosed in Ascend, its second Phase 3 study evaluating DT120 ODT for the treat...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/definium-therapeutics-says-first-patient-dosed-in-ascend-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/definium-therapeutics-says-first-patient-dosed-in-ascend-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634145218","title":"BRIEF-Definium Therapeutics Announces First Patient Dosed In Ascend","url":"https://stock-news.laohu8.com/highlight/detail?id=2634145218","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634145218?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:00","pubTimestamp":1778583658,"startTime":"0","endTime":"0","summary":"BRIEF-Definium Therapeutics Announces First Patient Dosed In AscendMay 12 (Reuters) - Definium Therapeutics Inc DFTX.O:DEFINIUM THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN ASCEND, THE SECOND PHASE 3","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nTUA1J1TPL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634221890","title":"Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 Odt in Major Depressive Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2634221890","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634221890?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:00","pubTimestamp":1778583604,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nTUA1J1TPL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":10,"totalSize":200,"code":"91000000","status":"200"}]}}